Development costs at St George Mining Ltd (ASX:SGQ, FRA:S0G, OTC:SGQMF))'s Araxá Project in Brazil will fall after the State of Minas Gerais signed a preferential goods tax regime covering project build-out and processing infrastructure.
Under the approved regime, equipment and other materials acquired for Araxá’s development — including items for a pilot plant and any future full-scale industrial plant — will be exempt from the State goods tax, which St George said can be as high as 18% and is typically applied at the time of purchase.
AuMEGA Metals Ltd (ASX:AAM, TSX:AUM, OTCQB:AUMMF, FRA:FRA: MA30) is looking to raise up to C$10 million through a brokered LIFE offering, with the bulk of the funds to be directed towards exploration in Newfoundland and Labrador.
The company plans to issue up to 42,553,191 flow-through shares at C$0.0470 each, 55,147,059 charity flow-through shares at C$0.0544 each and 125,000,000 common shares at C$0.040 each.
Crocs, Inc. (NASDAQ:CROX) shares rose nearly 20% following the company’s fourth quarter 2025 earnings report, as the footwear maker delivered results that exceeded Wall Street expectations.
The company reported adjusted earnings of $2.29 per share, beating the consensus estimate of $1.92 by about 19%.
NanoViricides (NYSE-A:NNVC), a clinical-stage biotechnology company developing broad-spectrum antiviral therapies, has filed for Orphan Drug Designation (ODD) with the US Food and Drug Administration (FDA) for its lead candidate NV-387 as a treatment for MPox.
If granted, the designation could provide NanoViricides with tax credits for clinical trials, exemption from certain user fees, and up to seven years of market exclusivity after approval.
VivoPower International PLC (NASDAQ:VVPR, FRA:51J) said it has completed a $30 million strategic private investment in public equity (PIPE) to support the expansion of its AI-focused data center infrastructure business.
The investment was structured as convertible preference shares with a conversion price of $6.80 per share and a 6% annual payment-in-kind (PIK) coupon.
Aftermath Silver Ltd (TSX-V:AAG, OTCQX:AAGFF, FRA:FLM1) has begun a pre-feasibility study (PFS) for its Berenguela silver-copper-manganese project in southern Peru.
The move follows the completion of a C$20 million equity financing and an 82-hole infill drilling program carried out in 2025, which intersected mineralization in 95% of the holes. An updated mineral resource estimate released in December materially improved confidence in the project’s geological model and confirmed robust silver and copper mineralization across key zones.
BioVie Inc (NASDAQ:BIVI, NASDAQ:BIVIW) said on Thursday that two abstracts highlighting research on its lead drug candidate bezisterim (NE3107) have been accepted for presentation at the 2026 American College of Psychiatrists annual meeting in Bonita Springs, Florida.
The abstracts, which focus on bezisterim’s potential in Alzheimer’s disease and Long COVID, will be presented as posters on February 18.
Seeing Machines Ltd (AIM:SEE, OTC:SEEMF, FRA:M2Z) is entering the decisive phase of Europe’s General Safety Regulation rollout, according to Stifel, which reiterated its 'buy' rating and 10.5p price target following Wednesday’s trading statement.
In a note titled “SEE KPIs – the ramp into GSR is real”, the broker said quarterly data confirmed that automotive original equipment manufacturer production and aftermarket sales were accelerating as the July GSR deadline approaches.
Sancus Lending Group Limited shares jumped 53% to 1.38p after the AIM-listed specialist property lender agreed to increase and extend its credit facility with Pollen Street Capital.
Sancus said it had entered into definitive legal agreements to expand the size of the facility from £200 million to £300 million and extend its maturity so that it will fall due no earlier than 11 February 2031.
Genflow Biosciences Ltd (LSE:GENF, OTCQB:GENFF, FRA:WQ5) shares opened 19.5% higher at 2.27p after the company reported positive preliminary interim results from its SLAB clinical trial in aged dogs.
The London-listed biotechnology group, which develops gene therapies for age-related diseases, said treated animals showed improved survival and functional outcomes during the dosing period.
IXICO PLC told investors it has added around £1.5 million of contracted revenue after extending an agreement tied to a global Phase 2 clinical trial in Huntington’s Disease.
The AIM-listed neuroscience imaging and biomarker analytics group said the extension follows continued progress in the study with one of the world’s leading international pharmaceutical companies, although it did not name the customer.
Biotechnology group says treated animals showed improved survival and functional measures in early-stage study
Genflow Biosciences Ltd (LSE:GENF, OTCQB:GENFF, FRA:WQ5) said positive preliminary interim results from its SLAB clinical trial showed improved survival and functional outcomes in aged dogs treated with its proprietary SIRT6 centenarian gene therapy.
Tamboran Resources Corporation (NYSE:TBN, ASX:TBN, OTC:TBNRL) says it remains on track to deliver first gas from the Beetaloo Basin in the third quarter of 2026, with its December quarterly outlining steady drilling progress, advancing infrastructure and strengthened funding.
The company’s Shenandoah South (SS) Pilot Project remains the centrepiece of its near-term development plans, with multiple wells drilled and stimulated and compression and pipeline infrastructure nearing completion.
Novo Resources Corp (TSX:NVO, OTCQX:NSRPF, ASX:NVO, FRA:1NOR) has sharpened its focus on a multi-jurisdiction gold and antimony exploration pipeline, with an upgraded exploration target at its Victorian Belltopper project and a series of drill-ready prospects emerging across Western Australia and New South Wales.
